Centessa Pharmaceuticals (CNTA) Operating Expenses (2020 - 2026)

Centessa Pharmaceuticals (CNTA) has 7 years of Operating Expenses data on file, last reported at $79.8 million in Q1 2026.

• Operating Expenses for Q1 2026 came in at $79.8 million, up 74.26% year-over-year; the trailing twelve-month figure through Mar 2026 was $256.7 million (up 21.8% YoY), and the FY2025 annual result was $222.7 million, up 10.76% from the prior year.
• Operating Expenses advanced to $79.8 million in Q1 2026 per CNTA's latest filing, from $68.5 million in the prior quarter.
• Over five years, Operating Expenses peaked at $79.8 million in Q1 2026 and troughed at $36.1 million in Q1 2024.
• A 5-year average of $52.5 million and a median of $48.9 million in 2023 frame the typical range for Operating Expenses.
• The sharpest annual moves came in 2022 and 2023: Operating Expenses soared 225.59% in 2022, then tumbled 31.27% in 2023.
• A 5-year view of Operating Expenses shows it stood at $41.6 million in 2022, then rose by 1.03% to $42.0 million in 2023, then soared by 77.44% to $74.6 million in 2024, then retreated by 8.19% to $68.5 million in 2025, then increased by 16.5% to $79.8 million in 2026.
• Business Quant data shows CNTA's Operating Expenses at $79.8 million in Q1 2026, $68.5 million in Q4 2025, and $53.8 million in Q3 2025.